Next generation sequencing: clinical applications in solid tumours

Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977;74(12):5463–7.

Maxam AM, Gilbert W. A new method for sequencing DNA. Proc Natl Acad Sci U S A. 1977;74(2):560–4.

Heather JM, Chain B. The sequence of sequencers: the history of sequencing DNA. Genomics. 2016;107(1):1–8.

Buermans HP, den Dunnen JT. Next generation sequencing technology: advances and applications. Biochim Biophys Acta. 2014;1842(10):1932–41.

Reuter JA, Spacek DV, Snyder MP. High-throughput sequencing technologies. Mol Cell. 2015;58(4):586–97.

Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet. 2016;17(6):333–51.

Naidoo N, Pawitan Y, Soong R, et al. Human genetics and genomics a decade after the release of the draft sequence of the human genome. Hum Genomics. 2011;5(6):577–622.

Genetics V. Veritas genetics launches $999 whole genome and sets new standard for genetic testing—Press Release. Veritas Genetics. 2016. https://www.veritasgenetics.com/documents/VG-launches-999-whole-genome.pdf . Accessed March 4th, 2016.

Samorodnitsky E, Jewell BM, Hagopian R, et al. Evaluation of hybridization capture versus amplicon-based methods for whole-exome sequencing. Hum Mutat. 2015;36(9):903–14.

Jennings LJ, Arcila ME, Corless C, et al. Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the association for molecular pathology and college of American pathologists. J Mol Diagn. 2017;19(3):341–65.

Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546–58.

Vogelstein B, Kinzler KW. The path to cancer—three strikes and you’re out. N Engl J Med. 2015;373(20):1895–8.

Simon R. Genomic alteration-driven clinical trial designs in oncology. Ann Intern Med. 2016;165(4):270–8.

Sims D, Sudbery I, Ilott NE, et al. Sequencing depth and coverage: key considerations in genomic analyses. Nat Rev Genet. 2014;15(2):121–32.

Marchetti A, Felicioni L, Buttitta F. Assessing EGFR mutations. N Engl J Med. 2006;354(5):526–8. author reply.

Do H, Dobrovic A. Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization. Clin Chem. 2015;61(1):64–71.

Oh E, Choi YL, Kwon MJ, et al. Comparison of accuracy of whole-exome sequencing with formalin-fixed paraffin-embedded and fresh frozen tissue samples. PLOS ONE. 2015;10(12):e144162.

Munchel S, Hoang Y, Zhao Y, et al. Targeted or whole genome sequencing of formalin fixed tissue samples: potential applications in cancer genomics. Oncotarget. 2015;6(28):25943–61.

1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, et al. A global reference for human genetic variation. Nature. 2015;526:68–74.

Tokheim CJ, Papadopoulos N, Kinzler KW, et al. Evaluating the evaluation of cancer driver genes. Proc Natl Acad Sci U S A. 2016;113(50):14330–5.

Diaz LA Jr., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579–86.

Wan JC, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223–38.

Hudecova I. Digital PCR analysis of circulating nucleic acids. Clin Biochem. 2015;48(15):948–56.

Cai X, Janku F, Zhan Q, et al. Accessing genetic information with liquid biopsies. Trends Genet. 2015;31(10):564–75.

Krishnamurthy N, Spencer E, Torkamani A, et al. Liquid biopsies for cancer: coming to a patient near you. J Clin Med. 2017;6(1):1–11.

Singh AP, Cheng H, Guo X, et al. Circulating tumor DNA in non-small-cell lung cancer: a primer for the clinician. JCO Precis Oncol. 2017;(1):1–13. https://doi.org/10.1200/po.17.00054 .

Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023–31.

Fiore RN, Goodman KW. Precision medicine ethics: selected issues and developments in next-generation sequencing, clinical oncology, and ethics. Curr Opin Oncol. 2016;28(1):83–7.

Knoppers BM, Nguyen MT, Senecal K, et al. Next-generation sequencing and the return of results. Cold Spring Harb Perspect Med. 2016;6(10):1–10.

Wang Y, Yang Q, Wang Z. The evolution of nanopore sequencing. Front Genet. 2014;5(449):1–20.